Effect on ovarian activity and ovulation inhibition of different oral dosages of levonorgestrel.

Objectives: To investigate the effect of different oral dosages of levonorgestrel (LNG) on ovarian activity and to identify the lowest dosage at which no ovulation occurred. Secondary objectives were to assess return of ovulation after stopping treatment, bleeding pattern, pharmacokinetic (PK) parameters and safety and tolerability.

Study Design: A parallel-group study with adaptive design was performed in 90 healthy women with proven ovulatory cycles.

Comparison of dienogest effects upon 3,3'-diindolylmethane supplementation in models of endometriosis and clinical cases.

Dienogest (DNG) administration is a well-established treatment for endometriosis but bleeding irregularities remain its main disadvantage. Changes in diet, mainly to vegetable consumption, are beneficial in the treatment of estrogen-related pathologies but their use for endometriosis has been poorly studied. In this study, addition of the phytochemical 3,3'-diindolylmethane (DIM) to DNG therapy has been investigated in in vitro and ex vivo models for endometriosis and in a small cohort of women with endometriosis.

Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission.

The pharmacokinetic profile of a new 4-g 5-aminosalicyclic acid (5-ASA) retention enema, Mesasal, was investigated. Nine patients with ulcerative colitis in remission and one patient with mild disease activity received one enema for seven consecutive nights. They were admitted to hospital for administration of the eighth enema.

Pharmaceutic development: mesalazine.

Sulfasalazine is composed of mesalazine and sulfapyridine linked by an azo bond. It has been shown that the clinical activity of sulfasalazine in the treatment of inflammatory bowel disease is derived from the mesalazine moiety, whereas most of the side effects are associated with the sulfapyridine component. To avoid the side effects associated with sulfapyridine, researchers have developed dosage forms that deliver mesalazine to the site of inflammation.

[Determination of the release of drugs from transdermal therapeutic systems. Presentation of a new release system].

A relatively simple release model for transdermal therapeutic systems (TTS) is described. The TTS is separated from the elution solvent by a semipermeable membrane. The elution solvent passes an elution channel with a flow rate of 3-9 ml/h.